BioRestorative Therapies Expands NY Facility to Advance Cell Therapy Clinical Trials
Company Expands Research Laboratories
BioRestorative Therapies, Inc. is taking a significant step forward by expanding its research laboratories in Melville, New York. This expansion will allow the company to enhance its capabilities in clinical production for its cell therapy candidates. The move underscores BioRestorative's commitment to advancing stem cell-based treatments and supports the growth of its innovative pipeline.
CEO Highlights Strategic Growth
Lance Alstodt, CEO of BioRestorative, expressed enthusiasm about the expansion, emphasizing its role in initiating Phase 2 clinical trials for their Disc/Spine program. He highlighted the importance of controlling internal clinical-grade cell manufacturing to support multiple product lines. Alstodt also mentioned that this expansion would enable the company to collaborate more effectively with clinical partners and advance proprietary technologies.
State-of-the-Art Manufacturing Facility
The new cGMP facility will feature advanced process development spaces and ISO 7 cleanrooms, equipped with cutting-edge scientific equipment. This state-of-the-art environment is designed to meet the highest standards of clinical-grade cell production. As the facility becomes operational, BioRestorative plans to recruit additional full-time employees to support its growing operations.
Commitment to Regulatory Compliance
BioRestorative is ensuring that its new manufacturing facility adheres to stringent regulations set by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This commitment to compliance guarantees that all clinical-grade cell production meets international standards. By following these guidelines, the company aims to maintain the highest quality in its therapeutic products.
Innovative Stem Cell Therapies on the Horizon
BioRestorative Therapies is at the forefront of developing cell and tissue-based treatments, primarily using adult stem cells. The company's two core programs focus on treating disc and spine diseases as well as metabolic disorders. With the expanded facilities, BioRestorative is poised to advance these therapies, bringing innovative solutions to patients in need.
Conclusion
BioRestorative Therapies' expansion of its Melville research laboratories marks a pivotal moment for the company. By investing in clinical production capabilities and adhering to strict regulatory standards, BioRestorative is well-equipped to advance its promising stem cell therapies. This growth not only enhances the company's research and development efforts but also positions it for future success in the life sciences industry.
Read the full article here:
businessinsider.com